Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-based quadruple therapy for antibiotic-resistant Helicobacter pylori after failure of standard triple therapy
ACTRN12615000493549Phase 4Completed
- Sponsor
- The University of Western Australia
- Start
- Jan 2012
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rabeprazole, bismuth subcitrate, rifabutin and ciprofloxacin in Helicobacter pylori infection (2 arms), sponsored by The University of Western Australia. Primary endpoint: Treatment success. Started Jan 2012; status: completed.
02
Drugs
rabeprazolebismuth subcitraterifabutinciprofloxacin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ACTRN12615000493549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000493549.